Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial

Cancer

Volumn 85, Issue 1, 1999, Pages 213-219

  Hidalgo, Manuel ^a,b   Hornedo, Javier ^a   Lumbreras, Carlos ^a   Trigo, José M ^a   Colomer, Ramón ^a   Perea, Sofía ^a   Gémez, Carlos ^a   Ruiz, Ana ^a   García Carbonero, Rocio ^a   Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Bacteremia; Low risk neutropenia and fever; Oral ofloxacin; Outpatient therapy

Indexed keywords

AMIKACIN; ANTINEOPLASTIC AGENT; CEFTAZIDIME; OFLOXACIN; TENIPOSIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; AMBULATORY CARE; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEFTAZIDIME; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; OFLOXACIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032893747     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D     Document Type: Article

References (20)

1. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyer JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-3.
2. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;144:2561-8.
3. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
4. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
5. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, et al. Outpatient treatment of febrile episodes in low-risk neutropenics patients with cancer. Cancer 1993;71:640-6.
6. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.
7. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-40.
8. Mayordomo JI, Rivera F, Díaz-Puente MT, Colomer R, PazAres L, Alonso S, et al. Improving treatment of chemotherapy-induced neurtopenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995;87:803-8.
9. Bodey JP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64: 328-40.
10. Neu HC. The place of quinolones in bacterial infections. Adv Intern Med 1991;36:1-32.
11. Fuchs PC. In vitro antimicrobial activity and susceptibility testing of ofloxacin: current status. Am J Med 1989;87(Suppl 6C):10S-3S.
12. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339: 1092-6.
13. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
14. Shenep JL, Hughes WT, Roberson PK, Blankenship K, Baker D, Meyer WH, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
15. Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993;398: 1323-31.
16. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-64.
17. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20: 557-60.
18. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of quinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7.
19. Manian FA. A prospective study of daily measurements of C-reactive protein in serum of adult patients with neutropenia. Clin Infect Dis 1995;21:114-21.
20. Schonbohn H, Schuler M, Kolbe K, Peschel C, Huber C, Bemb W, et al. Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia. Ann Hematol 1995; 71:161-8.